Savara is a clinical-stage biopharmaceutical company building treatment options for unusual respiratory conditions. Its lead item prospect can be an immunostimulator called molgramostim. Molgramostim is in section three scientific trials to deal with autoimmune pulmonary alveolar proteinosis, or aPAP. In accordance with Walter Isaacson's biography Elon Musk (2023), Musk https://financefeeds.com/wfe-warns-of-risks-in-otc-markets-promotes-listed-derivatives/